Abstract
We describe the case of a 44-year-old female patient on rituximab for the treatment of multiple sclerosis with undetectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG specific antibodies 18 days after the second dose of SARS-CoV-2 vaccine. Interferon-gamma release assay testing for SARS-CoV-2 was positive on day 19, demonstrating a robust T cell-mediated response despite the lack of an antibody-mediated response.
Keywords: Impaired humoral immunity; SARS-CoV-2; SARS-CoV-2 vaccination; T cell respone.
All Keywords
【저자키워드】 SARS-CoV-2, SARS-CoV-2 vaccination, Impaired humoral immunity, T cell respone., 【초록키워드】 Treatment, IgG, coronavirus, multiple sclerosis, SARS-CoV-2 vaccine, T cell, female, Patient, Interferon-gamma, humoral, cell-mediated response, acute respiratory syndrome, second dose, positive, robust, lack, specific antibody, Impaired, undetectable, 【제목키워드】 Case report, COVID-19 vaccination, Patient, seronegative, Interferon-gamma,
【저자키워드】 SARS-CoV-2, SARS-CoV-2 vaccination, Impaired humoral immunity, T cell respone., 【초록키워드】 Treatment, IgG, coronavirus, multiple sclerosis, SARS-CoV-2 vaccine, T cell, female, Patient, Interferon-gamma, humoral, cell-mediated response, acute respiratory syndrome, second dose, positive, robust, lack, specific antibody, Impaired, undetectable, 【제목키워드】 Case report, COVID-19 vaccination, Patient, seronegative, Interferon-gamma,
{{{ 추상적인 }}}
우리는 SARS-CoV-의 두 번째 접종 후 18일째에 감지할 수 없는 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) IgG 특이적 항체가 있는 다발성 경화증의 치료를 위해 리툭시맙을 투여받은 44세 여성 환자의 사례를 설명합니다. 2 백신. SARS-CoV-2에 대한 인터페론-감마 방출 분석 테스트는 19일째에 양성이었고, 항체 매개 반응이 없음에도 불구하고 강력한 T 세포 매개 반응을 보여주었습니다.
{{ 키워드: }} 체액성 면역 장애; 사스 코로나바이러스 2; SARS-CoV-2 예방접종; T 세포 반응.